Dr. Lal PathLabs Limited has announced it will host a conference call for investors and analysts on Thursday, April 30, 2026, at 5:30pm IST to discuss the company's financial and operating performance for the fourth quarter and full fiscal year 2026. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Management Representation

The conference call will feature key members of Dr. Lal PathLabs 's leadership team, including (Hon'ble) Brig. Dr. Arvind Lal – Executive Chairman, Mr. Shankha Banerjee – Chief Executive Officer, and Mr. Ved Prakash Goel – Group Chief Financial Officer & CEO – International Business. The management will initiate the call with a brief discussion on Q4 and FY26 financial and operating performance, which will be announced on the same day, followed by a question-and-answer session.

Conference Call Details

Participants are encouraged to pre-register through the provided link to receive dial-in numbers, passcode, and PIN for seamless connection to the conference call.

Company Overview

Dr. Lal PathLabs Limited operates as one of India's leading consumer healthcare brands in diagnostic services. As of March 31, 2025, the company maintains an integrated nationwide network comprising 298 clinical labs (including National Reference Lab at Delhi and Regional Reference Labs at Kolkata, Bangalore, and Mumbai), 6,607 Patient Service Centers (PSCs), and 12,365 Pick-up Points (PUPs).

The company's service catalogue includes 385 test panels, 3,172 pathology tests, and 1,455 radiology and cardiology tests as of March 31, 2025. In FY25 and FY24, Dr. Lal PathLabs collected and processed approximately 86 million samples and 78 million samples from 28.8 million and 27.6 million patients, respectively.

Contact Information

For further information, investors may contact Ved P Goel at Dr. Lal PathLabs Limited via email at ved.goel@lalpathlabs.com . Media and investor relations queries can be directed to Siddharth Rangnekar or Nishid Solanki at CDR India via email at siddharth@cdr-india.com and nishid@cdr-india.com , respectively.

Disclaimer

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like Government actions, local political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

-ENDS-

Dr. Lal Path Labs Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The diagnostic services company filed its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 09, 2026. Company Secretary and Compliance Officer Vinay Gujral submitted the documentation to both the National Stock Exchange of India Limited and BSE Limited.

RTA Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar & Share Transfer Agent. The RTA issued its confirmation certificate on April 6, 2026, which was subsequently enclosed with Dr. Lal PathLabs' regulatory filing.

Swapan Kumar Naskar, Associate Vice President & Head of the Delhi Branch at MUFG Intime India, confirmed that during the quarter ended March 31, 2026, the RTA did not receive any demat requests for processing. The certificate specifically noted that Dr. Lal PathLabs does not maintain any physical shares.

Corporate Structure Details

The filing included standard corporate identification details for both exchanges. Dr. Lal PathLabs trades on NSE under the symbol LALPATHLAB and on BSE with scrip code 539524. MUFG Intime India Private Limited operates under CIN U67190MH1999PTC118368 and functions as part of MUFG Corporate Markets, a division of MUFG Pension & Market Services.

This quarterly compliance filing represents routine regulatory adherence, ensuring transparency in share transfer and dematerialization processes as mandated by SEBI regulations for listed companies.